First-line TKIs plus concurrent cranial radiotherapy is a promising therapeutic strategy that leads to remarkable improvements in intracranial PFS and survival benefits for patients with EGFR-mutant NSCLC with BMs. Here, EGFR is linked to non-small cell lung carcinoma.